Aerosol Chamber and Interface Design for Optimizing Inspired Dose in Neonatal CPAP Devices
By designing a neonatal CPAP device in the neonatal CPAP device, the atomized drug and respiratory gas are mixed in the atomized room and delivered during inhalation, the problem of inconsistent drug delivery in the prior art is solved, and more stable drug inhalation and Higher drug deposition efficiency.
Patent Information
- Application Number
- CN202080038282.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-05-24
- Filing Date
- 2020-05-26
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2040-05-26
AI Technical Summary
The existing neonatal CPAP devices have inconsistent drug delivery at different gas flow rates, resulting in significant changes in inhalation doses and unable to achieve stable drug delivery.
A nebulization system is designed in which a nebulized drug is mixed with the respiratory gas in the nebulized chamber and is isolated from the respiratory system through the fluid passage, and airflow is introduced into the nebulization chamber only when the patient is inhaled to ensure the mixing of the drug with the airflow and Delivery to the patient.
The stability of drug delivery at different gas flow rates is achieved, the efficiency and percentage of drug deposition in the lungs is improved, the loss and waste of drugs are reduced, and the higher inhaled drug dose is ensured.
Smart Images

Figure CN114364421B_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority to U.S. Provisional Application No. 62 / 852,867, filed on May 24, 2019, entitled Design of an Aerosol Chamber and Interface for Optimizing Inhaled Doses in a Neonatal CPAP Device, and U.S. Provisional Application No. 62 / 852,862, filed on May 24, 2019, entitled Design of an Aerosol System and Interface for Delivering Clinically and Economically Viable Inhaled Doses in a Neonatal CPAP Device, the entire contents of which are incorporated herein by reference.
[0003] This application is related to U.S. application No. 15 / 933,205, entitled Aerosol Delivery Device, filed on March 22, 2018, U.S. application No. 15 / 933,217, entitled Improved Aerosol Delivery Systems and Methods, filed on March 22, 2018, U.S. application No. 15 / 933,219, entitled Aerosol Delivery Systems and Methods, filed on March 22, 2018, U.S. application No. 62 / 475,618, entitled Improved Aerosol Delivery Systems and Methods, filed on March 23, 2017, U.S. application No. 62 / 475,635, entitled Aerosol Delivery Device, filed on March 23, 2017, and U.S. application No. 62 / 475,603, entitled Aerosol Delivery Systems and Methods, filed on March 23, 2017, the entire contents of which are incorporated herein by reference. Background Art
[0004] Conventional interfaces for nasal CPAP consist of a gas inlet from the inspiratory limb and an outlet to the expiratory limb, as well as an interface to the patient via a nasal plug or a nasal mask. For example, conventional systems allow the introduction of aerosols through an auxiliary port before the inspiratory limb, wherein the aerosol flow is directed to the patient interface through a separate conduit. This solution requires continuous aerosol generation and airflow. By placing the aerosol generator between the airflow and the patient interface, the delivery of the drug can vary significantly based on the gas flow rate of the respiratory system. For example, in the case of a lower system gas flow rate (~0.5 liters / minute), the inhaled dose may increase by 30-45%, but in the case of a higher system gas flow rate (>6 liters / minute), the inhaled dose may be reduced to less than 6%. A more consistent drug delivery system is desired. Summary of the invention
[0005] Embodiments of the present invention provide a nebulization system and method in which aerosolized medication and respiratory gases are mixed within a nebulization chamber before being introduced into the patient's airway. The nebulization chamber can be isolated from the main flow path of the respiratory system. In other words, the respiratory gases within the nebulization chamber are intermittent, drawn only by the patient's inhalation, rather than being continuously pushed into the chamber by the respiratory system. This design helps maintain consistent drug delivery results because flow rate variations are reduced.
[0006] In one aspect, a nebulization system is provided. The nebulization system includes a respiratory system having an inspiratory limb and an expiratory limb. The system may also include an inlet connected to the inspiratory limb of the respiratory system. The system may also include an aerosol chamber, which is connected to the inlet via a fluid channel. The fluid channel can be configured to isolate the aerosol chamber from a continuous flow through the respiratory system. The system may also include a patient interface positioned at a first end of the aerosol chamber and an atomizing device positioned at a second end of the aerosol chamber, the second end being opposite to the first end. The atomizing device may include a reservoir configured to transfer the drug to a net of an aerosol generator and / or receive a certain volume of liquid drug to be atomized by the atomizing device. The aerosol chamber may be configured to mix the atomized drug from the atomizing device with the respiratory flow received from the respiratory system via the fluid channel.
[0007] In another aspect, an aerosol system includes an aerosol chamber and an atomizing device positioned at a first end of the aerosol chamber. The atomizing device may include a reservoir configured to receive a certain volume of liquid medicine to be atomized by the atomizing device. The system may also include an inlet, an outlet, and a fluid channel connecting an aerosol channel to one of the inlet or the outlet. The fluid channel may be configured to isolate the aerosol chamber from a continuous flow leading from the inlet to the outlet. The aerosol chamber may be configured to mix a respiratory flow received from a respiratory system via the fluid channel with atomized medicine from the atomizing device.
[0008] In another aspect, a method for delivering aerosolized medicine to a patient is provided. The method may include providing an aerosol system. The aerosol system may include a respiratory system, which includes an inspiratory limb and an expiratory limb, an inlet connected to the inspiratory limb of the respiratory system and an outlet connected to the expiratory limb of the respiratory system, wherein the outlet is in fluid communication with the inlet. The aerosol system may also include an aerosol chamber, which is connected to one of the inlet or outlet via a fluid channel. The fluid channel may be configured to isolate the aerosol chamber from a continuous flow leading from the inlet to the outlet. The aerosol system may also include a patient interface positioned at a first end of the aerosol chamber and an aerosol device positioned at a second end of the aerosol chamber, the second end being opposite to the first end. The aerosol device may include a reservoir, which is configured to receive a certain volume of liquid medicine to be aerosolized by the aerosol device. The aerosol chamber may be configured to mix the aerosolized medicine from the aerosol device with the respiratory flow received from the respiratory system via the fluid channel.
[0009] The method may also include docking a patient interface with an airway of the patient; and causing a respiratory stream to flow from the respiratory system through the inlet and the outlet. The method may also include atomizing a volume of liquid medication in a nebulizer chamber using a nebulizer, mixing the atomized medication with a portion of the respiratory stream that has been drawn into the chamber, and delivering the mixture of the atomized medication and the respiratory stream to the patient via the patient interface.
[0010] In one embodiment, a nebulizing device is provided. The device may include an aerosol chamber having a first end and a second end; and an aerosol generator, which is positioned at the first end of the aerosol chamber. The aerosol generator may be configured to aerosolize a certain volume of medicine into particles at a rate of at least 0.1 ml / min, and the particles have a mass mean aerodynamic diameter (MMAD) of less than about 3 μm. The device may also include a patient interface positioned adjacent to the second end of the aerosol chamber and a respiratory adapter, which is configured to connect the nebulizing device to the respiratory system and to shunt a portion of the airflow of the respiratory system to the aerosol chamber via a fluid channel. The aerosol chamber may be configured to mix part of the airflow with the aerosolized surfactant from the aerosol generator to be subsequently delivered to the patient via the patient interface. In some embodiments, the aerosol generator may include a reservoir, which is configured to receive a certain volume of liquid surfactant to be aerosolized by the aerosol generator. In some embodiments, the respiratory adapter may include a shunt mechanism, which is configured to shunt a portion of the airflow from the respiratory system to the aerosol chamber via a fluid channel. In some embodiments, a portion of the airflow may be a respiratory flow and is less than the amount of air that continues to reach the expiratory limb of the respiratory system. In some embodiments, the diversion mechanism may include at least one baffle that defines a fluid channel. At least one baffle may be configured to divert a portion of the airflow to the aerosol chamber via the fluid channel and to divert an additional portion of the airflow from the inspiratory limb to the expiratory limb. In some embodiments, at least one baffle may include a first baffle that defines a first airway and a second baffle that defines a second airway. In some embodiments, the first airway is disposed at a side end of the first baffle, the second airway is disposed outside the distal edge of the second baffle, and the side end and the distal edge extend in different directions so that the respiratory flow moves in multiple directions to pass through the first baffle and the second baffle.
[0011] In some embodiments, the device may include a catheter configured to deliver a volume of drug to the aerosol generator. The distal tip of the catheter has a diameter. The distal tip of the catheter may be positioned at a distance from the net that is less than or equal to the diameter. In some embodiments, the aerosol chamber may be generally funnel-shaped, such that the first end includes a wide portion of the aerosol chamber and the second end includes a narrow portion of the aerosol chamber. In some embodiments, the patient interface may include a nasal plug. In some embodiments, the fluid path defined by the fluid channel forms an angle of no more than 90 degrees with the upstream side of the flow path through the respiratory system. In some embodiments, the respiratory adapter may include an inlet configured to dock with an inspiratory limb of the respiratory system; and an outlet configured to dock with an expiratory limb of the respiratory system. In some embodiments, the fluid channel may be positioned so that the respiratory flow does not enter the aerosol chamber between the patient's breaths. In some embodiments, the device may include a fluid supply line coupled to the nebulizer; and a pump configured to deliver a volume of drug to a reservoir of the nebulizer via the fluid supply line. In some embodiments, the drug includes a surfactant.
[0012] In another embodiment, a nebulizing device may include an aerosol chamber and a nebulizing generator positioned at a first end of the aerosol chamber. The nebulizing generator may be configured to nebulize a certain volume of medicine into particles at a rate of at least 0.1 ml / min, and the particles have a mass mean aerodynamic diameter (MMAD) of less than about 3 μm. The device may also include a patient interface positioned at a second end of the aerosol chamber opposite to the first end; an inlet, the inlet is configured to be connected to an inspiratory limb of the respiratory system; an outlet, the outlet is configured to be connected to an expiratory limb of the respiratory system; and a fluid channel, the fluid channel connects the aerosol channel to at least one of the inlet and the outlet. The fluid channel may be configured to isolate the aerosol chamber from a continuous flow from the inlet to the outlet. The aerosol chamber may be configured to mix the respiratory flow received from the respiratory system via the fluid channel with the nebulized medicine from the nebulizing device.
[0013] In some embodiments, the aerosol chamber can be generally funnel-shaped, so that the first end includes the wide portion of the aerosol chamber and the second end includes the narrow portion of the aerosol chamber. In some embodiments, the patient interface includes a nasal plug or a nasal mask. In some embodiments, the fluid path defined by the fluid channel forms an acute angle with the upstream side of at least one of the inlet and the outlet, and the fluid channel is connected to at least one of the inlet and the outlet. In some embodiments, the inlet and the outlet can be configured to direct the gas flow from the inspiratory branch to the expiratory branch so that the respiratory flow does not enter the aerosol chamber between the patient's breaths. In some embodiments, the device may also include a fluid supply line connected to the nebulizer; and a pump, the pump being configured to deliver a certain volume of liquid medicine to the conduit of the nebulizer via the fluid supply line. In some embodiments, the inlet and the outlet are formed integrally.
[0014] In another embodiment, a method for delivering aerosolized medication to a patient is provided. The method may include providing an aerosolizing device, which may include an aerosol chamber; a respiratory adapter; an aerosol generator positioned at a first end of the aerosol chamber opposite the first end; and a patient interface positioned at a second end of the aerosol chamber. The method may also include docking the patient interface with the patient's airway; docking the respiratory adapter with the respiratory system; and using the respiratory adapter to divert a portion of the airflow of the respiratory system into the aerosol chamber when the patient inhales. The method may also include supplying a volume of liquid medication to the aerosol generator; using the aerosol generator to aerosolize a volume of liquid medication in the aerosol chamber to generate particles having a mass mean aerodynamic diameter (MMAD) of less than about 3 μm at a rate of at least 0.1 ml / min, the particles mixing with the airflow that has been introduced into the chamber; and delivering the mixture of aerosolized medication and airflow to the patient via the patient interface.
[0015] In some embodiments, the method may further include sensing the patient's inhalation using one or more respiratory sensors. In some embodiments, atomization of a certain volume of liquid medicine can be triggered based on the sensed inhalation of the patient. In some embodiments, the aerosol chamber can be generally funnel-shaped, so that the first end includes the wide part of the aerosol chamber, and the second end includes the narrow part of the aerosol chamber. In some embodiments, the airflow is sucked into the aerosol chamber by the vacuum created by the patient's inhalation at the patient interface. In some embodiments, the respiratory adapter includes an inlet and an outlet, and the aerosol chamber is connected to at least one of the inlet or the outlet via a fluid channel. The fluid channel can be arranged to isolate the aerosol chamber from the continuous flow leading from the inlet to the outlet. BRIEF DESCRIPTION OF THE DRAWINGS
[0016] Figure 1 is an isometric view of an atomization device according to an embodiment;
[0017] Figure 1A yes Figure 1 A cross-sectional view of an atomizing device;
[0018] Figure 2 Shown by Figure 1 The flow pattern of the atomizing device;
[0019] Figure 3 is an isometric view of an atomization device according to an embodiment;
[0020] Figure 3A yes Figure 3 A cross-sectional view of an atomizing device;
[0021] Figure 4A Shown by Figure 3 The flow pattern of the atomizing device;
[0022] Figure 4B Shown by Figure 3 The flow pattern of the atomizing device;
[0023] Figure 5A Shows the flow from the low flow breathing system through Figure 3 The flow pattern of the atomizing device;
[0024] Figure 5B Shows the flow from the low flow breathing system through Figure 3 The flow pattern of the atomizing device;
[0025] Figure 6 shows an isometric view of an atomization device according to an embodiment;
[0026] Fig. 6A yes Figure 6 A cross-sectional view of an atomizing device;
[0027] Figure 6B yes Figure 6 A cross-sectional view of an atomizing device;
[0028] Figure 6C yes Figure 6 A cross-sectional view of an atomizing device;
[0029] Fig.6D Shown by Figure 6 The flow pattern of the atomizing device;
[0030] Figure 7 Shown is a diagram of a fluid supply line and a breathing system connected to the Figure 6 Atomizing device;
[0031] Figure 8 An atomizing device connected to a source of medication is shown;
[0032] Fig. 9 Shown is a diagram of a device connected to a drug source and a controller. Figure 8 Atomizing device;
[0033] Fig.10 Shows Fig. 9 Controller;
[0034] Fig.11 Shows Fig. 9 A vial holder for a controller;
[0035] Fig.12 Shows Fig. 9 Source of medicines;
[0036] Fig.13 Shows Fig. 9 The functions of the controller;
[0037] Fig.14 is a flow chart of the process of delivering aerosolized medication to a patient;
[0038] Fig.15 is a bar graph showing an emitted dose rate using an atomizing device according to an embodiment;
[0039] Fig.16 is a bar graph showing emitted dose rate as a function of breathing rate and flow rate using a nebulizing device according to an embodiment. DETAILED DESCRIPTION
[0040] The following description provides only embodiments and is not intended to limit the scope, applicability or configuration of the present invention. On the contrary, the subsequent description of the embodiments will provide an enabling description for implementing the embodiments for those skilled in the art. It should be understood that various changes can be made in the functions and arrangements of the elements without departing from the spirit and scope of the present invention.
[0041] Embodiments of the present invention provide atomization systems and methods, wherein atomized drugs and respiratory gases are mixed in atomization chambers isolated from the direct current of the respiratory system, so that a small portion of the respiratory gases enter the atomization chamber, and most of the respiratory flow bypasses the chamber and passes through the expiratory limb of the respiratory system. Regardless of the flow rate from the respiratory system, such design considerations can ensure that the drug delivery rate is consistent. In addition, embodiments of the present invention provide improved atomization solutions, which can be connected to an existing respiratory system to transform the existing system so that it can deliver a reliable dose of atomized drugs to the patient's airway. In addition, the atomization system provided herein can include one or more respiratory sensors that enable the controller to predict the patient's inhalation, such as one or more flow sensors (e.g., current sensors), radar sensors (e.g., ultra-wideband (UWB) radar sensors for measuring chest displacement), CO2 sensors, high-speed temperature sensors, acoustic sensors, impedance plethysmography sensors, respiratory inductance plethysmography sensors, pressure sensors, etc., so as to allow the atomization of drugs during or before the patient's inhalation.
[0042] Embodiments of the present invention provide a nebulization system that isolates the nebulized medication from the main respiratory airflow to avoid interference and dilution of the aerosol generated during the inspiratory phase. This isolation can be achieved using baffles and / or other barriers designed to redirect the main flow from the inlet to the outlet without flushing the gas through the patient interface.
[0043] Embodiments of the present invention also generate and deliver surfactant aerosol only during the inhalation cycle (inhalation). Conventional devices deliver the aerosol continuously. However, infants can only inhale the aerosol during inhalation, so during exhalation (up to two-thirds of the respiratory cycle) the aerosol bypasses the airway and is lost and wasted. By limiting the generation of aerosol to only during inhalation and delivering the aerosol proximally to the nostrils, it is ensured that the highest percentage of surfactant is available for deposition in the lungs.
[0044] Embodiments of the present invention also generate aerosols near the patient interface to help increase the amount of aerosol delivered to the patient. Conventional nebulizers are placed somewhere in the inspiratory tubing of a ventilator or nCPAP circuit, where aerosols are generated within a continuous airflow. This greatly dilutes the aerosol being delivered and loses a lot in the continuous airflow, which usually exceeds the inspiratory flow of the subject. In contrast, the atomizing device of the present invention generates aerosols directly at the patient interface (such as a stuffy nose) and diverts a large amount of airflow from the nCPAP circuit away from the aerosol plume to significantly reduce aerosol losses in the continuous airflow of the circuit. The embodiment also uses an aerosol generator that emits aerosol surfactants at a rate of 0.3 ml / min or more with an undiluted surfactant, which is faster than previously reported use of other mesh nebulizers and reduces the administration time. Although mainly discussed with respect to the delivery of surfactants, it should be understood that other forms of drugs can be used with the atomizing system of the present invention to deliver aerosolized drugs to the lungs of patients.
[0045] In some embodiments, the atomization system described herein may include a reusable device controller and a disposable single-patient single-use atomization device, which includes a drug delivery circuit and / or a respiratory sensor. This atomization device is used as an independent drug delivery device, which is integrated with various ventilation devices (such as CPAP devices), and in some embodiments, it is not designed to be connected to a hospital network or the Internet. For example, the controller can be a multi-patient reusable component with a flat-panel touch screen display, electronic components and software. The controller can have three core functions: to detect inspiration via a respiratory sensor (which can be designed for use by a single patient) that can be attached to the patient's abdomen, to propel the suspension to the atomization device via an integrated feeding mechanism, and to generate an aerosol during inhalation at the nCPAP interface. These functions can occur synchronously with the infant's inhalation cycle. The flat-panel touch screen utilizes a graphical user interface (GUI) to allow the user to set and monitor delivery parameters, alarms and system diagnostics. Visual and audible alarms can be integrated into the controller. The cabin can be used to transmit signals from the respiratory sensor to the controller, and transmit signals to synchronize the generation of aerosols with the detected breathing. The reservoir from which the drug product is dispensed may be a vial in which the drug is provided.
[0046] In some embodiments, a disposable single-patient single-use nebulizer device includes a ventilation vial access device (VVAD) that facilitates access to a drug reservoir and is provided to the user in a separate package; and a drug feed tubing that includes a Luer connector (to the VVAD) and tubing that delivers the drug suspension from the Luer connector to an aerosol generator of the nebulizer device. The nebulizer device may also include an aerosol generator that may use a customized photo-defined aperture plate (PDAP) vibrating mesh that is unique in its ability to provide small droplet sizes and higher output rates. This is due to the innovative architecture of the PDAP mesh, which provides holes with diameters up to 20 times smaller than those found in traditional meshes. The aerosol generator is designed to distribute the aerosol proximally to the infant's airway and connect to a traditional nCPAP system.
[0047] The reusable controller is equipped with a built-in touch screen with a processor that monitors delivery parameters, alarms (visual and audible), and system diagnostics. The controller and capsule work in conjunction to detect inspiration via a breathing sensor that is attached to the infant's abdomen at one end and inserted into the capsule at the other end. The controller activates the drug feed mechanism, which drives drug delivery to the nebulizer to synchronize aerosol generation with the infant's inspiratory cycle.
[0048] The lyophilized surfactant is reconstituted in its original glass vial to produce a saline / surfactant suspension. The vial is connected to a drug delivery circuit that includes a drug feed tubing through a vented vial access device that pierces the vial septum, allowing air to vent into the vial, allowing the suspension to be emptied in a consistent manner. An integrated volumetric drug feed mechanism advances the surfactant suspension through the drug feed tubing and delivers it to a nebulizer (proprietary vibrating mesh) integrated into the drug delivery circuit interface. The interface uses a nasal prong. The interface is attached to the infant's clinical nCPAP circuit and placed on the infant, replacing the previous interface. The aerosol is then delivered in sync with the infant's inspiration triggered by a breathing sensor.
[0049] Although primarily discussed in the context of surfactants, it should be understood that the methods and devices of the present invention can be used with any liquid medication. For example, drugs such as, but not limited to, bronchodilators, anti-infectives, anti-virals, anti-inflammatory drugs, mucus regulating drugs, siRNA, PFOB, etc. can be utilized according to the present invention.
[0050] Go to Figure 1, an embodiment of a nebulization system is provided. Here, the nebulization device 100 is positioned on a first side of the aerosol chamber 102, wherein the patient interface 104 is positioned on the opposite second side of the nebulization chamber 102. The nebulization device 100 can be a sprayer or any other device configured to atomize a certain dose of liquid medicine. Such devices are described in U.S. Patent No. 5,758,637, U.S. Patent No. 6,235,177, U.S. Patent Publication No. 2015 / 0336115 and U.S. Patent Publication No. 2016 / 0130715, all of which are incorporated herein by reference. The nebulization device 100 may include a reservoir configured to receive and / or hold a certain amount of liquid medicine to be atomized. In some embodiments, the reservoir may be a "virtual reservoir" in the form of a conduit that is connected and extended between a fluid feed line and a net of the nebulization device 100. For example, the size of the conduit may be set to only hold about 10-15mcl of material, which may be collected in the conduit between atomization. The primary reservoir may be in the form of a vial containing medication, which via a feeding mechanism and feeding line may provide medication to the mesh via a catheter or dummy reservoir on a breath-by-breath basis. In some embodiments, the patient interface may include nasal prongs, endotracheal tubes, nasal cannula / mask, tracheostomy tube, and the like.
[0051] The system includes a respiratory adapter 106 configured to interface with an artificial respiration system, such as a ventilator, a humidifier, a continuous positive airway pressure (CPAP) machine, an nCPAP system, and / or a combination thereof. For example, the respiratory adapter 106 may include an inlet 108, such as an inlet baffle, configured to couple with an inspiratory limb of the respiratory system. For example, the inlet 108 may be an inlet baffle configured to interface with a Flexitrunk manufactured by Fisher & Paykel Healthcare. TM The route interface is coupled and directs the respiratory flow into the nebulization chamber 102. The inlet 108 can be coupled to the aerosol chamber 102, such as via a fluid path 110. In some embodiments, the inlet 108 is designed to redirect gas from the respiratory system to the nebulization chamber without increasing the patient's breathing resistance or work of breathing. This can be achieved by providing a fluid path 110 having a cross-sectional area of about 80% or more relative to the internal cross-sectional diameter of the patient interface 104.
[0052] Figure 1A Shows Figure 11. A cross-sectional view of a nebulization system of a nebulizer 100. Here, the aerosol generator 112 of the nebulizer 100 is shown as being positioned at the first end of the aerosol chamber 102 so that any drug atomized by the aerosol generator 112 is introduced into the nebulizer chamber 102. The aerosol generator 112 may include a net configured to generate aerosol particles. Conventional aerosol devices typically produce aerosols with an average droplet diameter in the range of 4 to 5 microns. However, the requirement for the aerosol droplet size of drugs delivered through the small airways of the respiratory tract of premature infants starting from the nostrils is typically less than 3 microns in diameter. Aerosol droplets larger than this size are prone to deposit in the nostrils and delivery tubing. If the droplets are much smaller than 1 micron, the droplets may not be deposited in the lungs and may be exhaled. This reduces the efficiency of dose delivery to the lungs. Embodiments of the present invention utilize mesh sizes that are designed to produce droplets with a median diameter between 2 and 3 microns. For example, in some embodiments, the aerosol generator 112 may include a light-defined aperture plate (PDAP) mesh configured to generate small aerosol particle sizes, such as less than 3 μm. Such a mesh is disclosed in U.S. Patent Publication No. 2016 / 0130715, which is previously incorporated by reference. Placing the aerosol generator 112 proximal to the patient interface 104 allows the aerosolized drug emitted during the inhalation cycle to be preferentially inhaled, with minimal interference with the continuous flow or bias flow through the respiratory system circuit. Here, the aerosol chamber 102 is shown as having a first end that is smaller than the second end. The inlet 108 is formed by a baffle, which is designed to draw a portion of the respiratory flow from the inhalation branch of the respiratory system via a fluid path 110 into the aerosol chamber 102 at a position close to the first end. The fluid path 110 is fluidly coupled to the inhalation branch so that the fluid path 110 has an angle of no more than 90 degrees relative to the respiratory flow through the branch and / or the upstream side of the inhalation branch at the junction between the branch and the inlet 108. This positioning helps to isolate the nebulizing chamber from the direct respiratory flow.For example, the respiratory flow is intermittently introduced into the aerosol chamber 102, which only occurs during the patient's inhalation.
[0053] exist Figure 2 Flow patterns through the nebulization system are shown in FIG, which shows an inspiratory limb 200 of the respiratory system supplying a respiratory gas flow. A portion of the respiratory gas flow can be drawn into the inlet 108 and introduced into the aerosol chamber 102 and the patient interface 104 via the fluid path 110. For example, when the patient inhales, the inhalation creates a vacuum in the nebulization chamber, which draws a volume of respiratory gas flow through the fluid path 110. Excess respiratory gas flow and / or exhaled gas can be exhausted through the expiratory limb 202 of the respiratory system.
[0054] Figure 1 , 1AThe nebulizer system of and 2 provides a higher and more consistent inhaled dose than conventional nebulizer systems within a range of airflows used with various nCPAP systems. For example, the nebulizer system described herein increases the inhaled dose from about 6% (as shown in conventional systems) to between about 40-50% with higher flow nCPAP systems (>6 liters / minute) and reduces variability with low flow systems (0.5 liters / minute), which also delivers an inhaled dose between about 40-50%.
[0055] Figure 3 Another embodiment of the atomizing device for providing a consistent dose of atomized medicine to a patient is depicted. The atomizing device may include an aerosol generator 300 positioned at the first end of an aerosol chamber 302, wherein a patient interface 304 is positioned at the second end opposite to the aerosol chamber 302. The aerosol generator 300 may be a nebulizer with a vibrating net, and the vibrating net may be selectively vibrated using a piezoelectric actuator. In certain embodiments, the aerosol generator 300 may include a reservoir, which is configured to receive and / or hold a certain volume of liquid medicine to be atomized. The aerosol generator 300 may be coupled to a medicine feed line 306, which is configured such as to deliver a certain volume of liquid medicine to the reservoir via a pump (not shown). The atomizing device may also include a cable 308 connected to a power source, but in some embodiments, the atomizing device may also be battery powered.
[0056] In some embodiments, the atomizing device may include an inlet 310 and an outlet 312, which may be connected to the inspiratory branch and the expiratory branch of the artificial respiration system, respectively. Potential artificial respiration systems include, but are not limited to, ventilators, humidifiers, CPAP machines, and / or combinations thereof. In some embodiments, the inlet 310 and the outlet 312 may be a single unit forming a flow path for the respiratory gas, while in other embodiments, the inlet 310 and the outlet 312 may be separate components coupled together. The inlet 310 and / or the outlet 312 may be configured to receive the end of a gas conduit of a respiratory system. For example, the inlet and / or outlet airflow baffles may support a one-way loop of a standard nCPAP circuit. This enables the baffle to minimize interference with the airflow from the inlet to the outlet, thereby generating less interference with the aerosol chamber 302.
[0057] like Figure 3A310 and / or the outlet 312. As shown in FIG. 314 , the atomizing device further includes a fluid flow path 314 connecting the aerosol chamber 302 with the inlet 310 and / or the outlet 312. As shown here, the fluid flow path 314 can deliver the breathing gas to a top portion of the aerosol chamber 302 adjacent to the aerosol generator 300, however, in some embodiments, other locations are also contemplated, such as a middle portion of the aerosol chamber 302 and / or a portion adjacent to the patient interface 304. The fluid flow path 314 can intersect the inlet 310 and / or the outlet 312 in such a manner that the fluid flow path 314 forms an angle of no more than 90 degrees with the upstream side of the inlet 310 and / or the outlet 312 and / or the flow path formed within the inlet 310 and / or the outlet 312, so that the gas flow path 314 is orthogonal to the inlet 310 and / or the outlet 312 or extends at least partially in a direction opposite to the gas flow through the inlet 310 and / or the outlet 312. This positioning of the fluid flow path 314 helps to isolate the aerosol chamber 302 from the continuous flow of respiratory gases flowing from the inlet 310 (inspiratory limb) to the outlet 312 (expiratory limb). This provides several benefits. First, isolating the aerosol chamber 302 from the continuous flow prevents the aerosolized drug from being "blown away" or diluted by the airflow. Second, the isolation allows the aerosol chamber 302 to be preloaded with aerosolized drug immediately before a respiratory event, while also being able to preserve any drug left over from the previous breath.
[0058] In some embodiments, a portion of the breathing gas may be drawn through fluid flow path 314 and into aerosol chamber 302 to mix with the aerosolized medicament. A portion of the breathing gas drawn into aerosol chamber 302 may be drawn in via a vacuum created by the patient inhaling at patient interface 304.
[0059] The aerosol chamber 302 has an internal geometry that is optimized to direct the plume toward the patient interface 304 with minimal impact. Specifically, the aerosol chamber 302 is designed so that the aerosol generator 300 is positioned opposite the patient interface 304. In addition, the aerosol chamber 302 is designed to have a generally funnel-shaped profile, which helps reduce impact as the aerosol leaves the aerosol generator 300 by providing a wider portion that tapers (linearly or nonlinearly) to a narrow portion adjacent to the patient interface 304. This design also helps to minimize the size of the aerosol chamber 302.
[0060] Figure 4A and 4B Depicts the passage from a high flow breathing system through Figure 3 and 3A314. The inspiratory flow flows through the inlet 310 at a rate of 8 liters / minute while the patient inhales at a rate of 1 liter / minute. The pressure at the expiratory branch connected to the outlet 312 is 5 cm of H2O. When the patient inhales through the patient interface 304, a portion of the respiratory gas is drawn through the fluid flow path 314 and into the aerosol chamber 302.
[0061] Figure 5A and 5B Depicts the passage from a low flow breathing system through Figure 3 and 3A The inspiratory flow path of the atomizing device is shown in FIG. 310. The inspiratory flow flows through the inlet 310 at a rate of 2 liters / minute while the patient inhales at a rate of 1 liter / minute. The pressure at the expiratory branch connected to the outlet 312 is 5 cm of H2O. Similar to the high flow embodiment, when the patient inhales through the patient interface 304, a portion of the respiratory gas is drawn through the fluid flow path 314 and into the aerosol chamber 302. Figure 5B As seen in , the portion of the respiratory flow drawn into aerosol chamber 302 is introduced into the patient's airway via patient interface 304 .
[0062] Figures 6 to 6D Another embodiment of a nebulizing device 600 is shown. Here, similar to those described above, an aerosol generator 612 ( Figures 6A to 6D The aerosol generator 612 may include a reservoir configured to receive and / or hold a certain amount of liquid medicine to be atomized. For example, in some embodiments, the atomizing device 600 may include at least one drug supply port 614 configured to be connected to a drug supply line (not shown) for delivering liquid medicine to the aerosol generator 612 (such as to the reservoir, if any). In some embodiments, the reservoir may be in the form of an elongated conduit extending between the drug supply port 614 and the aerosol generator 612. In some embodiments, the patient interface 604 may include a nasal plug, an endotracheal cannula, a nasal cannula / mask, a tracheostomy tube, etc. The atomizing device 600 may also include at least one power connection 640. As shown, the power connection 640 is a port that allows a power cable to be connected to the atomizing device 600 to provide power and / or control commands to the aerosol generator 612.
[0063] The device includes a respiratory adapter 606, which is configured to dock with an artificial respiration system, such as a ventilator, a humidifier, a continuous positive airway pressure (CPAP) machine, an nCPAP system, and / or a combination thereof. For example, the respiratory adapter 606 may include an inlet 608, such as an inlet baffle, which is configured to be connected to the inspiratory branch 650 of the respiratory system. The respiratory adapter 606 may also include an outlet 616, such as an outlet baffle, which is configured to dock with the expiratory branch 652 of the respiratory system. For example, as shown, the inlet 608 and / or the outlet 616 can be configured to be inserted and retained (such as, using friction fit and / or other fixing mechanisms) in the conduits of the inspiratory branch 650 and the expiratory branch 652, respectively. In other embodiments, the inlet 608 and / or the outlet 616 can be configured to be larger than the conduit of the respiratory system, so that the conduits of the inspiratory branch 650 and / or the expiratory branch 652 can be inserted and retained (such as, using friction fit and / or other fixing mechanisms) in the inlet 608 and the outlet 616, respectively. It should be appreciated that other techniques for interfacing the inlet 608 and / or the outlet 616 with the respiratory system may be utilized, and the inlet 608 and outlet 616 need not be interfaced using the same technique.
[0064] Fig. 6A Shows Figure 6618. Here, the aerosol generator 612 of the atomizing device 600 is shown as being positioned at the first end 618 of the atomizing chamber 602, so that any drug atomized by the aerosol generator 612 is introduced into the aerosol chamber 602. For example, the drug can be delivered to the aerosol generator 612 via a drug supply port 614 communicated with the reservoir. In some embodiments, the reservoir can be a "virtual reservoir" in the form of a conduit 632 that delivers the drug to the surface of the aerosol generator 612. The virtual reservoir conduit 632 can be connected to a drug source, such as a vial, via a fluid line connected to the drug supply port 614. The most distal tip 634 of the conduit 632 can have a diameter less than or equal to the distance between the proximal surface of the net of the tip 634 and the aerosol generator 612. This size design ensures that the droplets of liquid drug ejected from the tip 634 are large enough to contact and transfer to the net of the aerosol generator 612. Surface tension ensures that liquid stays on the surface of the net and spreads along the surface of the net so that all or substantially all liquids are atomized. This allows atomizing device 600 to operate in any orientation, thereby allowing patients (such as infants) to treat when they lie on their side, lie on their backs or lie prone. For example, in some embodiments, the tip of drug supply port 614 can be positioned between about 5 to 40 microns from the surface of aerosol generator 612, and tip 364 has a diameter less than or equal to the distance. As shown in the figure, aerosol generator 612 is placed adjacent to patient interface 604, because the only component that separates aerosol generator 612 from patient interface 604 is aerosol chamber 602. This placement of aerosol generator 612 adjacent to patient interface 604 allows the atomized medicine emitted during the inhalation cycle to be preferentially inhaled, wherein the interference with the continuous flow or bias flow through the respiratory system circuit is minimal. Here, aerosol chamber 602 is shown as having a first end 618 less than second end 620, which helps to reduce impact when aerosol leaves atomizing device 600.
[0065] The inlet 608 may be formed by a baffle designed to draw a portion of the respiratory flow from the inspiratory limb 650 of the respiratory system via a fluid path into the aerosol chamber 602 at a location proximate to the first end, which will be related to Figure 6B and 6CDescribed in more detail. In some embodiments, the inlet 608 can be designed to redirect gas from the respiratory system to the aerosol chamber 602 without substantially increasing the patient's respiratory resistance or work of breathing (e.g., inspiratory pressure), or at least to any significant extent. This can be accomplished by providing a fluid path in the respiratory adapter 606 that includes a plurality of baffles that direct a portion of air from the inspiratory limb (just enough for inhalation) into the aerosol chamber 602 in a manner that significantly reduces turbulence in the airflow drawn into the atomizing device 600, thereby creating more laminar flow within the aerosol chamber 602.
[0066] Figure 6B and 6C Two halves of atomizing device 600 are shown. Although shown as two separable components, it should be understood that atomizing device 600 may include any number of components that may be coupled together (such as using connecting / mating features), and / or may be formed from a single component that may be formed by known molding, 3D printing, and / or other known and unknown manufacturing techniques. Figure 6B As shown, a portion of the atomizing device 600 includes a fluid flow path, which includes a plurality of baffles. In the illustrated embodiment, the atomizing device 600 includes a first baffle 622, which directs a large amount of flow from the inspiratory branch 650 to the expiratory branch 652, while allowing a portion of the flow from the inspiratory branch 650 to enter the aerosol chamber 602. For example, the baffle 622 can be generally U-shaped, with one or both ends open to form an airway 624 between the baffle 622 and the side wall of the housing of the atomizing device 600, the airway 624 allowing a small amount of air to flow through the end of the baffle 622, while the body of the baffle 622 prevents the remaining air from passing through the baffle 622, and instead directs the air to the expiratory branch 652. It should be understood that although a U-shaped baffle 622 is used in the present embodiment, other shapes can also be used to meet the needs of specific applications.
[0067] The atomizing device 602 may include a second baffle 626 positioned adjacent to the baffle 622. As shown, the second baffle 626 is in the form of a generally U-shaped barrier, which is oriented in a direction opposite to the baffle 622 (however, other shapes and orientations of the second baffle 626 are also possible, such as a second baffle 626 extending in a generally linear manner within the width of the interior of the atomizing device 600 and / or a second baffle that is curved or otherwise oriented in the same direction as the baffle 622). In some embodiments, the first baffle 622 and the second baffle 626 may be a single component, such as by sharing a middle portion, while other embodiments utilize baffles that are separate components. As shown, the second baffle 626 extends all the way to the side wall of the housing, but a gap is left between the distal edge of the second baffle 626 and the top of the housing of the atomizing device 602, which provides a path for air to enter the atomizing chamber 602. Thus, as shown, when the patient inhales at the patient interface 604, a portion of the gas supplied by the inspiratory branch 650 is drawn through the airway 624 on one or more ends of the baffle 622, wherein the air is pushed upward above the second baffle 624 and forms a generally laminar flow within the aerosol chamber 602. However, it should be understood that in some embodiments, the second baffle 626 can direct air to the bottom of the housing and / or to a central opening formed between the top baffle and the bottom baffle, rather than directing the airflow toward the top of the housing. Any number of designs of baffles and / or other diverter mechanisms (including valves) can be used to help isolate the aerosol chamber 602 from direct flow of respiratory gases from the respiratory system while providing some flow of respiratory gases during patient inhalation.
[0068] Figure 6C Another part of the atomizing device 600 docked with the first part is shown. This part of the atomizing device 600 defines a seat 628 for receiving an aerosol generator 612, a drug supply port 614 and / or other related components. A matching feature 630 can also be provided, which receives the baffle 622 and fixes it in place. For example, the matching feature 630 can define a groove or a channel that is set to the top edge of the baffle 622 in size and shape. This connection ensures that the baffle 622 can extend from the bottom surface of the housing of the atomizing device 600 to the top surface of the housing, which ensures that only the airflow passing through the airway 624 on either end of the baffle 622 exceeds the baffle 622, while most of the airflow is directed to the outlet 616.
[0069] Fig.6DThe flow pattern of the airflow drawn from the inspiratory limb 650 via the inlet 608 into the nebulizing device 600 is shown. For example, air from the inspiratory limb 650 (which may pass through a humidifier) may pass through the respiratory adapter 606, where the baffle 622 redirects most of the air into the expiratory limb 652 via the outlet 616. As described above, the baffle 622 provides one or more airways 624 that allow a portion of the airflow from the inspiratory limb 650 to be drawn inward each time the patient inhales. This portion of the air is inhaled through the airway, where it encounters the second baffle 626. The second baffle 626 pushes the air drawn through the end of the baffle 622 upward, where the air flows over the second baffle 626 and into the nebulizing chamber 602. As shown here, the air is introduced into the aerosol chamber 602 at a location near the first end 618 of the adjacent aerosol generator 612. In other embodiments, the airflow may be introduced into the aerosol chamber 602 at other locations. As just one example, a baffle similar to baffle 622 can be used to introduce air near the side wall of the aerosol chamber 602. As shown here, air is introduced into the nebulizer chamber 602 at a position near the first end 618 of the adjacent aerosol generator 612. In other embodiments, the airflow can be introduced into the nebulizer chamber 602 at other positions. As just one example, a baffle similar to baffle 622 can be used to introduce air near the side wall of the nebulizer chamber 602. It should be understood that other designs and / or positions of baffles can be used to introduce air into the nebulizer chamber 602 while isolating the nebulizer chamber 602 from the direct current in the respiratory system. In addition, some embodiments can utilize other mechanisms to divert some air from the respiratory system to the nebulizer chamber 602 during each inhalation of the patient. For example, some embodiments can incorporate one or more one-way valves, which are arranged between the nebulizer chamber 602 and the inspiratory branch 650 and / or the expiratory branch 652. The one or more valves seal and / or otherwise isolate the nebulizing chamber 602 from the respiratory system until the patient inhales, at which time the one or more valves open and allow a small volume of respiratory flow into the nebulizing chamber 602 .
[0070] By using a series of baffles that direct a small amount of air from the inspiratory branch 650 to the aerosol chamber 602, embodiments of the present invention ensure that the air drawn into the aerosol chamber 602 can have less turbulence and more laminar flow, which provides better deposition of the drug in the lungs. The baffles can be designed so that the gas / air drawn over the baffles is at or close to the inspiratory flow of the infant (which is much lower than the gas passing through the inspiratory branch 650). It should be understood that, although two baffles are used in the illustrated embodiment, before the airflow is introduced into the aerosol chamber 602, other numbers and arrangements of baffles can be used to reduce the turbulence in the airflow from the inspiratory branch 650 without significantly increasing the amount of inhalation force required to draw air into the patient's airway. In addition, although U-shaped baffles are shown, it should be understood that other baffle designs can also be used, which both limit the amount of airflow drawn into the aerosol chamber 602 during each inhalation and reduce the amount of turbulence in such airflow. This also helps to reduce dilution of the aerosolized drug in the air supplied by the inspiratory limb 650.
[0071] Figure 7 The diagram shows the connection status with both the fluid supply line 700 and the breathing system 702. Figures 6 to 6D nebulizer 600. As shown, a first end of a fluid supply line 700 is coupled to a drug supply port 614. For example, in some embodiments, the drug supply port 614 includes a tip protruding outwardly from the body of the nebulizer 600. The opening of the fluid supply line 700 can be mounted above the tip, allowing fluid from the fluid supply line 700 to pass through the drug supply port 614 and enter the reservoir and / or conduit 634 for subsequent delivery to the aerosol generator 602. A second end (not shown) of the fluid supply line 700 can be coupled to a fluid source, such as a vial (or other type of container) of a liquid drug.
[0072] The respiratory adapter 606 can be coupled to the respiratory system 702. As shown here, the inlet 608 is coupled to the inspiratory limb 650 of the respiratory system 702, while the outlet 616 and the expiratory limb 652 are shielded. Air and / or other respiratory gases can pass from the inspiratory limb 650 to the respiratory adapter 606, wherein one or more diverting mechanisms, such as valves, baffles, etc., can divert a portion of the gas flow to the aerosol chamber 602 via the fluid path, while directing the remaining larger portion of the gas flow of the respiratory system 702 through the expiratory limb 652 through the respiratory adapter 606.
[0073] The nebulizer cable 704 is connected to the power connection 640. The nebulizer cable 704 is configured to deliver power to the aerosol generator 602, and provide operating commands (such as commands to control when to actuate the aerosol generator 602 and how long to actuate). For example, a controller (not shown) can be connected to the atomizing device 600 via the nebulizer cable. The controller can use one or more respiratory sensors to monitor the patient's respiratory cycle. Based on this information, the controller can use the nebulizer cable 704 (or other communication link) to send a signal, which activates the pump to deliver liquid to the aerosol generator 612 and actuate the aerosol generator 612 to atomize the medicine.
[0074] Figure 8 Another embodiment of atomizing device 800 is shown. Atomizing device 800 can be similar to above-mentioned atomizing device 600. As shown in the figure, atomizing device 800 is connected with drug source 802. Drug source 802 can be any container of the drug of certain volume. As shown in the figure, drug source 802 is a vial connected to the drug port of atomizing device via Luer connection 804 and the length of fluid supply line 806. Also connected with atomizing device 800 is a sprayer cable 808 that can be connected with a controller (not shown). Sprayer cable 808 terminates in a cabin 810 that can be used to connect atomizing device 800 and / or a respiratory sensor and a controller.
[0075] Fig. 9 Atomizing device 800 connected to a drug source 802 and a controller 812 is shown. The controller can be configured to cause liquid medicine to be delivered to the atomizing device 800 via a fluid supply line 806 and to actuate the atomizing device 800. In some embodiments, the controller 812 can actuate the atomizing device 800 based on the detected patient inhalation. For example, the controller 812 can be connected to a breathing sensor 814, which can detect the start, duration and / or end of the patient's inhalation. In some embodiments, the breathing sensor 814 can be a sensor similar to a Graseby sensor, which can be positioned against the patient's trunk (abdomen and / or chest) to detect the patient's breathing cycle. As such an example, the controller 812 can receive a signal from the breathing sensor 814, which indicates that the patient starts to inhale. The controller 812 can then send a command, which causes a certain volume of liquid medicine to be supplied to the aerosol generator of the atomizing device 800 and causes the aerosol generator to activate during inhalation to atomize the liquid medicine.
[0076] In some embodiments, the breathing sensor 814 and / or the nebulizing device 800 can be directly coupled to the controller 812. In other embodiments, the capsule 810 and / or other adapters can be used to connect the breathing sensor 814 and / or the nebulizing device 800 to the controller 812. For example, in some embodiments, connecting the breathing sensor to the capsule includes inserting a connection, such as a sliding luer, into a port of the capsule 810. In this embodiment, the breathing sensor 814 can be adhered and / or otherwise attached to the abdomen of the patient to begin sensing the inhalation cycle.
[0077] Fig.10 Controller 812 is shown. Controller 812 includes a user interface 818, such as a display screen. In some embodiments, user interface 818 can be a touch screen. Controller 812 can include one or more input devices, such as buttons, dials, keypads, touch screens, etc., which allow users to interact with controller 812 to adjust settings, such as dosage levels, etc. Controller 812 can also include multiple ports 820, which can be used to connect controller 812 to peripheral units, such as atomizing device 800 and / or breathing sensor 814. In some embodiments, controller 812 can include one or more indicators 824, such as LEDs, which are configured to warn the user of the status of various features. For example, indicator 824 can notify the user whether atomizing device 800 and / or breathing sensor 814 are properly connected, whether the power supply 832 of controller 812 is valid (i.e., inserted and / or whether the battery (if present) is charging or charged), whether any fault in the system has been detected, etc. In some embodiments, indicator 824 can be integrated into user interface 818. The housing 822 of the controller 812 may include a holder 826 configured to securely receive the drug source 802, such as Fig.11 In this embodiment, the drug source 802 is a vial secured in an inverted orientation within the holder 826, thereby allowing the entire contents of the drug source 802 to be expelled from the drug source 802, pumped and / or otherwise delivered from the drug source 802 to the atomizing device 802.
[0078] Fig.12 A source of medication 802 is shown. Here, the source of medication 802 is in the form of a vial with a vented vial access device (VVAD) 828 attached. The VVAD 828 can include a removable cap 830 that seals the opening of the VVAD 828 when attached to the VVAD 828. The VVAD 828 can also include a filter 832 that helps minimize aerosols within the vial and fluid supply line 806, minimize surface contamination, and offset vial pressure. In use, the cap 830 can be removed and a port (not shown) can be attached to a Luer connector to couple the source of medication 802 to the fluid supply line 806.
[0079] In certain embodiments, atomizing device as herein described comprises an aerosol generator that can be connected to various artificial respiration systems.Aerosol generator can receive liquid medicine from fluid source by fluid delivery conduit.In operation, the fluid pumping from fluid source is delivered to aerosol generator by fluid delivery conduit with pump, and there, before patient inhales and / or simultaneously atomizes fluid.In certain embodiments, fluid delivery conduit can be filled with fluid before treatment to ensure fast delivery (for example, fluid is preloaded in aerosol generator).Pump can be controlled with controller, and controller arranges time for delivery and dosage of fluid.
[0080] The controller includes one or more processors, which execute instructions stored on one or more memories to drive the operation of pumps and aerosol generators. For example, the memory may include instructions, which indicate the amount of fluid to be pumped to the aerosol generator in each dose for each actuation of the aerosol generator, how much fluid to be pumped in a specific time period, etc. The stored instructions may be based on the patient's body shape, the patient's age, the patient's gender, the type of medicine, fluid additives, the amount of desired aerosols, etc. The memory also includes instructions for activating the aerosol generator. As shown in the figure, the controller is connected to the aerosol generator with a cable (i.e., cable), but in some embodiments, the controller may also be wirelessly connected to the aerosol generator. The cable carries a signal, which activates the piezoelectric (or other) actuator inside the aerosol generator. When the piezoelectric actuator operates, it vibrates the vibrating member, and the vibrating member subsequently atomizes the fluid to be delivered to the patient (i.e., by inhalation). Therefore, the memory may include instructions for controlling when the piezoelectric actuator starts, stops, vibrates at a frequency or multiple frequencies, etc.
[0081] Atomization system as described herein can improve therapeutic efficacy by arranging the time for the generation of aerosol. For example, an aerosol delivery system can start atomizing medicine before the patient inhales. In this way, the aerosol delivery system utilizes increased airflow at the beginning of inhalation. When the inhaled air brings the medicine deeper into the patient's lungs, this increases the drug delivery to the patient. Once inhalation (for example, for spontaneous breathing) is detected, the aerosol delivery system can also atomize medicine.
[0082] The aerosol delivery system coordinates the delivery of the drug using one or more breathing sensors to determine when the patient inhales and how long. These breathing sensors can communicate with the controller via a wired connection and / or a wireless connection. In some embodiments, the aerosol delivery system can use a combination of breathing sensors to provide redundancy and / or more accurate monitoring of the patient's breathing cycle. As just one example, an aerosol delivery system can use a flow sensor in combination with a radar sensor to monitor both airflow and chest movement. As another example, an aerosol delivery system can use a flow sensor, a radar sensor, and a plethysmographic sensor to monitor the breathing cycle. It should be understood that in a given application, any number and / or any combination of breathing sensors can be used to monitor the patient's breathing cycle.
[0083] In some embodiments, a flow sensor is coupled to the gas delivery conduit to sense changes in airflow during inhalation (e.g., forced, assisted, or spontaneous breathing). In some embodiments, the flow sensor may also be coupled to the gas return conduit to detect the start and end of exhalation. And in other embodiments, the aerosol delivery system may include a flow sensor coupled to the gas delivery conduit and the gas return conduit. When the controller receives data from the flow sensor, the controller may monitor the breathing pattern to predict when the patient is about to breathe. The ability to predict when inhalation begins enables the aerosol delivery system to prepare aerosolized medication for immediate inhalation. More specifically, the aerosol delivery system is able to preload the fluid on a vibratory member in the aerosol generator so that the fluid can be atomized before inhalation. Since flow detection is not a hysteresis indicator, the flow sensor can quickly detect unusual or spontaneous inhalations for aerosol delivery (e.g., less than 10 milliseconds from the start of inhalation).
[0084] The patient's inhalation (if the patient is on mandatory ventilation) can be predicted by using one or more breathing and / or flow sensors to track the patient's breathing pattern and / or ventilation cycle. Then, the controller uses the tracked data to predict when the subsequent inhalation will begin. This allows the controller to instruct the pump to deliver the fluid from the fluid source to the aerosol generator 16 before inhalation. The controller can also signal the aerosol generator to start atomizing the fluid at the appropriate time, such as within a predetermined time period (e.g., + / - 0.5 seconds) before and / or during the predicted inhalation. In this way, the aerosol is prepared for the patient when the inhalation begins. Although the aerosol delivery system is able to predict the breathing cycle to generate an aerosol for the patient, the aerosol delivery system is also able to use a breathing sensor to identify spontaneous / irregular breathing that is not part of the normal pattern. Once spontaneous breathing is identified, the aerosol delivery system can immediately pump the fluid to the aerosol generator for delivery to the patient.
[0085] Fig.13 An example of the function of controller 812 is shown. As shown in Figure A, controller 812 can receive a signal from breathing sensor 814, which indicates that the patient has started to inhale. Then, controller 812 sends a command to start delivering a certain volume of medicine to the aerosol generator, which is activated to nebulize liquid medicine, as shown in Figures B to D. In some embodiments, controller 812 can be programmed to nebulize medicine only in the first part of inhalation, thereby allowing the last part of inhalation to inhale chase air to help deliver the nebulized medicine to the deep lung. For example, as shown in various figures, controller 812 causes nebulization of medicine only in the first 80% of each inhalation, thereby allowing the last 20% of each inhalation to draw chase air into the patient's airway. It should be understood that other nebulization modes can be used. For example, nebulization of medicine can be performed in the first 50% to 90% of each inhalation (more commonly between 60% and 80%, and even more commonly between 70% and 80%). More than 80% of the time is associated with more aerosol in the upper airway that is exhaled before reaching the lower airway. This allows the last 10% to 50% (more typically between about 20% to 40%, and even more typically between 20% and 30%) of the inspiration to be used to draw chase air into the patient's airway.
[0086] Fig.14 900 is a flow chart of a process of delivering aerosolized medication to a patient. Process 900 can start at frame 902 by providing an aerosol device. The aerosol device can be similar to any of those described herein. For example, the aerosol device can include an aerosol chamber; a breathing adapter; an aerosol generator positioned at a first end of the aerosol chamber opposite to the first end; and a patient interface positioned at a second end of the aerosol chamber. Process 900 also includes docking the patient interface with the patient's airway at frame 904. In some embodiments, the patient interface can include a nasal plug that can be inserted into the patient's nostrils. In some embodiments, the nasal plug can be removably fixed to the aerosol device so that nasal plugs of different sizes can be attached to the aerosol device to accommodate patients with different sizes. At frame 906, the breathing adapter can be docked with the respiratory system. For example, the breathing adapter can include an inlet that can be connected to the inspiratory limb of the respiratory system; and an outlet that can be connected to the expiratory limb of the respiratory system.
[0087] Once the atomizing device has been docked with the patient and the respiratory system, frame 908 may include using a respiratory adapter to shunt a portion of the airflow of the respiratory system to the aerosol chamber when the patient inhales. For example, the respiratory adapter may include one or more baffles configured to direct most of the airflow through the respiratory system to the expiratory limb, while introducing a small amount of airflow into the aerosol chamber via a fluid channel. At frame 910, a certain volume of liquid medicine may be supplied to an aerosol generator. At frame 912, an aerosol generator is used to atomize a certain volume of liquid medicine in the atomizing chamber to generate particles having a mass mean aerodynamic diameter (MMAD) of less than about 3 μm at a rate of at least 0.1 ml / min, and the particles are mixed with the airflow that has been introduced into the chamber. For example, liquid medicine may be supplied to a net, such as a PDAP net, which may then vibrate to atomize the liquid medicine. At frame 914, a mixture of atomized medicine and airflow is delivered to the patient via a patient interface.
[0088] In some embodiments, the process may include sensing the patient's inhalation using one or more respiratory sensors. In such embodiments, atomization of a certain volume of liquid medicine is triggered based on the sensed inhalation of the patient. For example, a respiratory sensor may detect inhalation. A controller (such as controller 812) may receive an indication of inhalation and send a command to start delivering a certain volume of medicine to an aerosol generator, which activates to atomize liquid medicine. In some embodiments, controller 812 may be programmed to atomize medicine only in the first portion of the inhalation, thereby allowing the last portion of the inhalation to inhale chase air to help deliver the atomized medicine to the deep lungs.
[0089] Example
[0090] In vitro experiments were conducted using the atomizer device according to the present invention to determine the effective emitted dose of the drug. Figures 6 to 6D The patient adapter of the nebulizer device shown (here, in the form of a nasal prong) is docked with a collection filter test lung (Enigma) and / or a modified small animal ventilator (Harvard Apparatus) to perform simulated infant inhalation (volume, rate and inspiratory:expiratory ratio). The simulation is performed using two different sized nasal prongs (larger nasal prongs (5560) and smaller nasal prongs (4030)). Fig.15 As shown in the bar graph, the larger the size of the nasal plug, the higher the dose emitted. Notably, the larger nasal plug (5560) resulted in an emitted dose between 68% and 72%, while the smaller nasal plug (4030) resulted in an emitted dose between about 35% and 37%.
[0091] The airflow was then set to 6 liters per minute (LPM), 8 LPM, and 10 LPM, with breathing rates of 60 breaths per minute (BPM), 80 BPM, 100 BPM, and 120 BPM. The emitted dose rate was then measured at each combination of air flow rate and breathing rate. Fig.16 As shown, airflow has an effect on delivery efficiency, where a larger flow rate results in a slightly lower delivery efficiency. For example, at a lower flow rate (6LPM), a larger nasal plug (5560) produces an emission dose of nearly 50% to about 60% at the extreme end of the tested respiratory rate, while at a higher flow rate (10LPM), the emission dose ranges from about 42% to about 47%. It is worth noting that as the respiratory rate increases, the efficiency difference associated with the greater flow rate becomes less obvious. For example, the emission dose rate at 60BPM ranges from about 44% to about 60%, while the emission dose rate at 120BPM ranges from about 42% to about 51%. Based on these results, it is determined that the aerosol generator described herein is capable of achieving consistent drug inhalation doses within the clinically relevant ranges of respiratory rates (60 to 120BPM) and CPAP flows (6 to 10LPM) typically used with bubble and ventilation CPAP systems.
[0092] The methods, systems, and devices discussed above are examples. Some embodiments are described as processes depicted as flow charts or block diagrams. Although each can describe the operations as sequential processes, many operations can also be performed in parallel or simultaneously. In addition, the order of the operations can be rearranged. The process can have additional steps not included in the figure. Moreover, the embodiments of the method can be implemented by hardware, software, firmware, middleware, microcode, hardware description language, or any combination thereof. When implemented in software, firmware, middleware, or microcode, the program code or code segment for performing the associated tasks can be stored in a machine-readable medium, such as a storage medium. The processor can perform the associated tasks.
[0093] It should be noted that the systems and devices discussed above are intended to be examples only. It must be emphasized that various embodiments may omit, replace or add various programs or components as appropriate. In addition, the features described in certain embodiments may be combined in various other embodiments. Different aspects and elements of the embodiments may be combined in a similar manner. In addition, it should be emphasized that technology is developing and therefore, many elements are examples and should not be interpreted as limiting the scope of the present invention.
[0094] Specific details are given in the description to provide a thorough understanding of the embodiments. However, it will be appreciated by those skilled in the art that embodiments may be practiced without these specific details. For example, known structures and techniques are shown without unnecessary details to avoid obscuring the embodiments. This description provides only example embodiments and is not intended to limit the scope, applicability or configuration of the present invention. On the contrary, the foregoing description of the embodiments will provide an enabling description for implementing embodiments of the present invention to those skilled in the art. Various changes may be made in the functions and arrangements of elements without departing from the spirit and scope of the present invention.
[0095] The methods, systems, devices, figures and tables discussed above are examples. Various configurations may omit, replace or add various programs or components as appropriate. For example, in alternative configurations, the methods may be performed in a different order than described, and / or the various stages may be added, omitted and / or combined. In addition, the features described with respect to certain configurations may be combined in various other configurations. Different aspects and elements of the configurations may be combined in a similar manner. In addition, the technology is developing, and therefore many of the elements are examples and do not limit the scope of the invention or the claims. In addition, the technology discussed herein may provide different results with different types of context-aware classifiers.
[0096] Although illustrative and presently preferred embodiments of the disclosed systems, methods, and machine-readable media have been described in detail herein, it should be understood that the concepts of the present invention may be otherwise differently embodied and employed, and the appended claims are intended to be interpreted to include such variations unless limited by prior art.
[0097] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly or conventionally understood. As used herein, the articles "a" and "an" refer to one or more than one (i.e., one or at least one) of the grammatical objects of an object. As an example, "an element" can represent one element or more than one element. As used herein, "about" and / or "near" refer to measurable values, such as amount, duration in time, etc., including changes of ±20% or ±10%, ±5% or +0.1% with the specified value, because such changes are applicable to the background of the systems, devices, circuits, methods and other embodiments described herein. As used herein, "substantially" refers to measurable values, such as amount, duration in time, physical properties (such as, frequency), etc., also including changes of ±20% or ±10%, ±5% or +0.1% with the specified value, because such changes are applicable to the background of the systems, devices, circuits, methods and other embodiments described herein. As used herein, including in the claims, as used in the list of items beginning with "at least one" or "one or more", "and" indicates that any combination of the listed items can be used. For example, a list of "at least one of A, B, and C" includes any of the combinations A or B or C or AB or AC or BC and / or ABC (i.e., A and B and C). Furthermore, to the extent that items A, B, or C may appear or be used more than once, multiple uses of A, B, and / or C may form part of the contemplated combinations. For example, a list of "at least one of A, B, and C" may also include AA, AAB, AAA, BB, etc.
[0098] Several embodiments have been described, and those skilled in the art will recognize that various modifications, alternative configurations, and equivalents may be used without departing from the spirit of the present invention. For example, the above elements may be merely components of a larger system, wherein other rules may take precedence over the application of the present invention or otherwise modify the application of the present invention. In addition, many steps may be taken before, during, or after considering the above elements. Accordingly, the above description should not be considered to limit the scope of the present invention.
[0099] Furthermore, when used in this specification and the following claims, the words "comprises," "including," "contains," "has," "includes," and "comprising" are intended to specify the presence of stated features, integers, components or steps, but do not preclude the presence or addition of one or more other features, integers, components, steps, actions or groups.
Claims
1. An atomizing device, include: an aerosol chamber having a first end and a second end; an aerosol generator positioned at the first end of the aerosol chamber, wherein the aerosol generator is configured to aerosolize a volume of the medicament into particles at a rate of at least 0.1 ml / min, the particles having a mass mean aerodynamic diameter (MMAD) of less than 3 μm; a patient interface positioned adjacent said second end of said aerosol chamber; as well as A breathing adapter configured to connect the nebulizer device to a breathing system and to divert a portion of the airflow of the breathing system to the aerosol chamber via a fluid channel, wherein: the respiratory adapter comprising a first baffle defining a first airway and a second baffle defining a second airway, the first baffle and the second baffle being configured to divert the portion of the airflow from the respiratory system into the aerosol chamber via the fluid passage and to divert an additional portion of the airflow from an inspiratory limb to an expiratory limb; the fluid passageway being positioned to deliver the portion of the gas flow to a portion of the aerosol chamber adjacent the aerosol generator; as well as The aerosol chamber is configured to mix the portion of the gas flow with aerosolized surfactant from the aerosol generator for subsequent delivery to a patient via the patient interface.
2. The atomizing device according to claim 1, in: The aerosol generator includes a reservoir configured to receive a volume of liquid surfactant to be aerosolized by the aerosol generator.
3. The atomizing device according to claim 1, in: The portion of the air flow is respiratory flow and is less than the amount of air that continues to the expiratory limb of the respiratory system.
4. The atomizing device according to claim 1, in: The first air channel is arranged at a side end of the first baffle; The second air channel is disposed outside the distal edge of the second baffle; as well as The side ends and the distal edge extend in different directions such that the airflow moves in multiple directions to pass through the first baffle and the second baffle.
5. The atomizing device according to claim 1, further comprising: include: a catheter configured to deliver the volume of medicament to the aerosol generator, wherein: The distal-most tip of the catheter has a diameter; and The distal-most tip of the catheter is positioned at a distance from the mesh that is less than or equal to the diameter.
6. The atomizing device according to claim 1, in: The aerosol chamber is generally funnel-shaped such that the first end comprises a wide portion of the aerosol chamber and the second end comprises a narrow portion of the aerosol chamber.
7. The atomizing device according to claim 1, in: The patient interface includes nasal prongs.
8. The atomizing device according to claim 1, in: A fluid path defined by the fluid passage forms an angle of no greater than 90 degrees with an upstream side of a flow path through the respiratory system.
9. The atomizing device according to claim 1, in: The breathing adapter comprises: an inlet configured to interface with an inspiratory limb of the respiratory system; and An outlet is configured to interface with an expiratory limb of the respiratory system.
10. The atomizing device according to claim 9, in: The fluid passageway is positioned such that the airflow does not enter the aerosol chamber between breaths of the patient.
11. The atomizing device according to claim 1, further comprising: include: a fluid supply line coupled to the atomizing device; as well as A pump is configured to deliver the volume of medicament to a reservoir of the nebulizing device via the fluid supply line.
12. The atomizing device according to claim 1, in: The drug includes a surfactant.
13. An atomizing device, include: Aerosol chamber; an aerosol generator positioned at a first end of the aerosol chamber, wherein the aerosol generator is configured to aerosolize a volume of a medicament into particles at a rate of at least 0.1 ml / min, the particles having a mass mean aerodynamic diameter (MMAD) of less than 3 μm; a patient interface positioned at a second end of the aerosol chamber opposite the first end; an inlet configured to couple with an inspiratory limb of a respiratory system; an outlet configured to couple with an expiratory limb of the respiratory system; a fluid passage coupling the aerosol chamber with at least one of the inlet and the outlet; a first baffle defining a first air passage; as well as a second baffle defining a second airway, the first baffle and the second baffle being configured to divert a portion of the airflow from the respiratory system into the aerosol chamber via the fluid passage and to divert an additional portion of the airflow from the inspiratory limb to the expiratory limb, wherein: the fluid passageway being positioned to deliver respiratory flow to a portion of the aerosol chamber adjacent the aerosol generator; The fluid passage is configured to isolate the aerosol chamber from a continuous flow from the inlet to the outlet; as well as The aerosol chamber is configured to mix the respiratory flow received from the respiratory system via the fluid passage with aerosolized medicament from the nebulizing device.
14. The atomizing device according to claim 13, in: The aerosol chamber is generally funnel-shaped such that the first end comprises a wide portion of the aerosol chamber and the second end comprises a narrow portion of the aerosol chamber.
15. The atomizing device according to claim 13, in: The patient interface comprises nasal prongs or a nasal mask.
16. The atomizing device according to claim 13, in: A fluid path defined by the fluid passage forms an acute angle with an upstream side of at least one of the inlet and the outlet to which the fluid passage is coupled.
17. The atomizing device according to claim 13, in: The inlet and the outlet are configured to direct a flow of gas from the inspiratory limb to the expiratory limb such that the respiratory flow does not enter the aerosol chamber between breaths of the patient.
18. The atomizing device according to claim 13, further comprising: include: a fluid supply line coupled to the atomizing device; as well as A pump is configured to deliver a volume of liquid medication to a conduit of the nebulizing device via the fluid supply line.
19. The atomizing device according to claim 13, in: The inlet and the outlet are integrally formed.
